Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 83 of 101 for:    ETHINYL ESTRADIOL AND DROSPIRENONE
Previous Study | Return to List | Next Study

Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being (COSME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00988910
Recruitment Status : Completed
First Posted : October 2, 2009
Last Update Posted : June 26, 2014
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the symptoms and satisfaction for women taking drospirenone (DRSP)-containing combined oral contraceptives in comparison with women taking other kind of combined oral contraceptives.

Condition or disease Intervention/treatment
Contraception Drug: EE30-DRSP (Yasmin, BAY86-5131) Drug: Other combined oral contraceptives

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 632 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study on the Effects of DRSP-Containing Combined Oral Contraceptives (Yasmin,Yasminelle) and Other Combined Oral Contraceptives on the General and Sexual Well-Being in COC Users
Study Start Date : January 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2010
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Group 1 Drug: EE30-DRSP (Yasmin, BAY86-5131)
DRSP-containing combined oral contraceptives according to the normal routine praxis
Group 2 Drug: Other combined oral contraceptives
Other combined oral contraceptives according to the normal routine praxis


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Psychophysical well-being evaluated by the Psychological General Well-Being Index (PGWBI) [ Time Frame: at 12 months ]
  2. Sexual well-being evaluated by the Female Sexual Function Index (FSFI) [ Time Frame: at 12 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy women using Combined Oral Contraceptive (COC)
Criteria

Inclusion Criteria:

  • According to the label of the prescribed Combined Oral Contraceptive (COC)
  • first Combined Oral Contraceptive use or previous Combined Oral Contraceptive use
  • intention to use current COC for 1 year at least

Exclusion Criteria:

  • Contraindications listed in the label of the prescribed Combined Oral Contraceptive (COC)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00988910


Locations
Layout table for location information
Italy
Many Locations, Italy
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
Click here to find results for studies related to Bayer Healthcare products.  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00988910     History of Changes
Other Study ID Numbers: 14182
YA0711IT ( Other Identifier: Other company ID )
First Posted: October 2, 2009    Key Record Dates
Last Update Posted: June 26, 2014
Last Verified: June 2014
Keywords provided by Bayer:
Combined Oral Contraceptives
COC
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Drospirenone and ethinyl estradiol combination
 Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female